Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease

Movement Disorders : Official Journal of the Movement Disorder Society
Jordi Gomez-RamirezJ M Brotchie

Abstract

L-dopa-induced dyskinesia (LID) remains a major complication of the treatment of Parkinson's disease. The neural mechanisms underlying LID are thought to involve overactivity of striatal glutamatergic neurotransmission, with resultant underactivation of the output regions of the basal ganglia. Histamine H3 heteroreceptors can reduce glutamate and gamma-aminobutyric acid (GABA) transmission in the striatum and substantia nigra reticulata, respectively. Thus, we tested whether the histamine H3 receptor agonists immepip and imetit can alleviate LID in the MPTP-lesioned marmoset model of Parkinson's disease. Coadministration of immepip (1 mg/kg) with L-dopa (15 mg/kg) was associated with significantly less total dyskinesia than L-dopa alone. When dyskinesia was separately rated as chorea and dystonia, coadministration of L-dopa with either immepip or imetit (both 10 mg/kg) significantly reduced chorea but had no effect on dystonia. The antidyskinetic actions of the H3 agonists were not accompanied by alteration of the antiparkinsonian actions of L-dopa. However, immepip (10 mg/kg), when administered as monotherapy, significantly increased parkinsonian disability compared to vehicle. Overall, the results obtained in this study sugge...Continue Reading

References

May 14, 1987·Nature·J M ArrangJ C Schwartz
Oct 1, 1987·Pharmacology, Biochemistry, and Behavior·H SershenA Lajtha
May 15, 1971·Lancet·J L WeissT N Chase
Jul 1, 1973·Journal of the Neurological Sciences·J A SharpeR R Tasker
Oct 1, 1969·Archives of Neurology·M D YahrM M Hoehn
Jun 1, 1995·Naunyn-Schmiedeberg's Archives of Pharmacology·G CoruzziH Timmerman
Jan 25, 1996·European Journal of Pharmacology·E A Clark, S J Hill
Apr 16, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·R K PearceC D Marsden
Oct 2, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·P J BlanchetT N Chase
Nov 25, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·J M Brotchie
Nov 11, 1999·Archives of Neurology·L V MetmanT N Chase
Dec 22, 1999·Naunyn-Schmiedeberg's Archives of Pharmacology·H PrastA Philippu
Feb 23, 2000·Neuroreport·A Molina-HernándezJ A Arias-Montaño
Apr 29, 2000·Experimental Neurology·O V AnichtchikP Panula
Oct 29, 2000·Trends in Neurosciences·J A ObesoC W Olanow
Oct 29, 2000·Trends in Neurosciences·J G NuttF Stocchi
Nov 9, 2000·The European Journal of Neuroscience·O V AnichtchikP Panula
Jun 8, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·P Del DottoU Bonuccelli
Aug 3, 2001·Nature Reviews. Neuroscience·E BezardC E Gross
Oct 24, 2001·Brain : a Journal of Neurology·A BerardelliM Hallett
Dec 19, 2001·Neuropharmacology·A Molina-HernándezJ A Arias-Montaño
Dec 26, 2001·Molecular Pharmacology·Jordi Gomez-RamirezIsaac Blanco
Dec 5, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Susan H FoxJonathan Brotchie
Jun 12, 2003·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Yves LambertyHenrik Klitgaard
Jul 31, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Juha-Matti SavolaJonathan M Brotchie
Oct 14, 2003·Experimental Neurology·Brian HenryJonathan M Brotchie
Nov 26, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Michael P HillHenrik Klitgaard
Jun 16, 2004·Neuroscience Letters·Enrique Sánchez-Lemus, José-Antonio Arias-Montaño
Oct 8, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Sarah ThrelfellSusan A Greenfield
Oct 30, 2004·Annals of Neurology·Incarnation AubertErwan Bezard
Dec 23, 2004·Journal of Neural Transmission·J M BrotchieK Venderova
May 17, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Mario van der SteltJonathan M Brotchie

❮ Previous
Next ❯

Citations

Jun 12, 2009·Current Neurology and Neuroscience Reports·James B KoprichJonathan M Brotchie
Mar 28, 2008·BMC Medical Genetics·Elena García-MartínJosé Ag Agúndez
Oct 19, 2016·Molecular Pharmacology·Gustavo Nieto-AlamillaJosé-Antonio Arias-Montaño
Mar 19, 2014·Trends in Neurosciences·Bart A Ellenbroek, Bibinaz Ghiabi
Aug 8, 2014·Neuroscience and Biobehavioral Reviews·Erich H SchneiderRoland Seifert
Jun 21, 2013·Nature Reviews. Neuroscience·Pertti Panula, Saara Nuutinen
Aug 21, 2008·Nature Reviews. Neuroscience·Peter Jenner
Mar 11, 2018·The Journal of Pharmacology and Experimental Therapeutics·Nicolas VeyresPhilippe Huot
Jan 16, 2013·Pharmacological Reviews·Philippe HuotJonathan M Brotchie
Mar 24, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Tom H JohnstonSusan H Fox
Sep 2, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Naomi P VisanjiSusan H Fox
Sep 3, 2008·Journal of Neurochemistry·Sarah ThrelfellSusan A Greenfield
Aug 2, 2015·Experimental Neurology·Linnea LentzRobert S Raike

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.